Lumps, Lab Work, and a Little AI: A Tech’s Guide to Canine Lymphoma

Speakers
Kevin Choy, BSc (Hons), BVSc (Hons 1), MS, DACVIM (Oncology)
Jessica West, LVT

Session Title
Lumps, Lab Work, and a Little AI: A Tech’s Guide to Canine Lymphoma

Synopsis
Dr. Kevin Choy will provide a comprehensive overview of current diagnostic approaches for canine lymphoma, including cytology, flow cytometry, immunohistochemistry, and molecular testing. He will introduce the role of artificial intelligence in veterinary oncology and discuss how AI-driven drug response prediction reports can support clinical decision-making and personalized treatment planning for canine lymphoma and leukemia. Joining him, Jessica West, LVT will offer practical guidance on fine-needle aspirate (FNA) sample collection, sharing best practices and techniques for obtaining high-quality samples.

‍

Presentations

When AI Disappoints: Improving Outcomes with Real-World Clinical Data

Veterinary Cancer Society Annual Conference 2025

Lumps, Lab Work, and a Little AI: A Tech’s Guide to Canine Lymphoma

Presentations

When AI Disappoints: Improving Outcomes with Real-World Clinical Data

Ethos Discovery Stratified Outcomes for Lymphoma in Dogs (SOLID) Study: Informing Subclassification & Prognosis

Optimizing the first line therapy of canine B-cell lymphomas via machine learning

Boosting the power of AI-based treatment outcome predictions for canine lymphoma by combining tumor and germline genetic biomarkers and live-cell analytics

Decoding Feline Lymphoma: From Diagnosis to Prognosis

Novel Genetic Biomarkers of Chemotherapeutic Response in Canine Lymphoma and Improved Predictive Power With Integration of Machine Learning

Improving Canine Lymphoma Treatment Outcomes by Individualizing Drug Selection using Machine-Learning-Based Predictive Models

Treatment-specific risk stratification of feline lymphoma based on unsupervised clustering of flow cytometry results

Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support

AI-driven Personalized Medicine for Cancer Care

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

Impact of AI on clinical practice and outcome

Canine Lymphoma Diagnostics Past, Present and Future: How AI technology and genetics are pushing the boundaries in veterinary medicine

ImpriMed: AI-driven Personalized Medicine for Pet Cancer Care

Reinventing precision medicine: from dogs to humans

ImpriMed Research Update

Identification of Novel Predictive Biomarkers of Anticancer Drug Responses in Canine B-Cell Lymphoma Using Targeted NGS

ImpriMed Research Update

Drugs predicted to be effective using artificial intelligence (AI) double the clinical response rate in canines with relapsed B-cell lymphoma

Precision medicine for pet cancer care

ImpriMed: Experiences from the eyes of an oncologist in clinical practice

Predicting dynamic clinical outcomes of (L-)CHOP chemotherapy for canine lymphoma patients using an artificial intelligence model

ImpriMed: A data-driven, personalized chemotherapy drug testing service for canine blood cancer patients

Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test

From dog to human: precision medicine for comparative oncology

ImpriMed: precision medicine for pet cancer care

Individualizing chemotherapy for canine lymphoma based on ex vivo drug sensitivity test